This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > PLX-PAD for injured gluteal musculature following arthroplasty

< Back

PLX-PAD for injured gluteal musculature following arthroplasty



May 2021

PLX-PAD is in development for the treatment of hip fractures. Hip fractures are when the bones related to the hip are damaged. They can occur at any age, however it is most common in the older population. This leads to pain and difficulty moving. Hip replacements, surgery which replaces damaged areas of the hip with artificial implants, is a common treatment for hip fractures. As the surgery requires cutting the muscles either at the front or back of the pelvis, to access the hip and leg bone, this can lead to muscle weakening. There are no medicinal options for treating muscle injury after hip replacement. PLX-PAD is an intramuscular (into muscle) injection that includes cells to promote muscle regeneration. PLX-PAD cells respond to the body’s distress signals, which are sent from the site of injury, by secreting proteins to help the body to i) grow blood vessels to supply damaged tissue, ii) heal muscle and iii) dampen the inflammatory response (which is aggravated by injury). PLX-PAD is in development to promote muscle injury recovery for people undergoing hip replacement, which may reduce recovery time in this patient population.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts